Article
Cell Biology
Tadej Fevzer, Primoz Pozenel, Kaja Zajc, Natasa Tesic, Urban Svajger
Summary: This study presents a novel and superior maturation cocktail for dendritic cells (DCs) in the production of DC-based vaccines. The new cocktail, which includes TLR-3 agonist, tumor necrosis factor, interleukin, interferon, and TLR-8 stimulation, enhances the efficacy of the DC vaccines by promoting the expression of co-stimulatory molecules, migratory capacity, and immune response. It demonstrates the potential for improving the manufacturing protocols of next-generation DC vaccines.
Review
Biochemistry & Molecular Biology
Farhan Ullah Khan, Puregmaa Khongorzul, Ahmed Aziz Raki, Ashwini Rajasekaran, Denis Gris, Abdelaziz Amrani
Summary: Type 1 diabetes is caused by the destruction of pancreatic beta cells mediated by T cells. Dendritic cells play a crucial role in the initiation and development of this disease by presenting antigens to activate and regulate the immune response. Recent advancements in understanding dendritic cell function and regulation have led to the development of potential therapeutic strategies for treating type 1 diabetes.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Engineering, Biomedical
Yanni Ge, Jiaojiao Zhang, Kai Jin, Ziqiang Ye, Wei Wang, Zhuxian Zhou, Juan Ye
Summary: This study developed a photothermal agent, copper sulfide@ovalbumin (CuS@OVA), with an effective photothermal effect on tumors. CuS@OVA can optimize the tumor microenvironment and stimulate an adaptive immune response, enhancing the antitumor efficiency of immune checkpoint blockade (ICB) and suppressing tumor growth and metastasis.
ACTA BIOMATERIALIA
(2023)
Article
Immunology
Taegeun Song, Yongjun Choi, Jae-Hyung Jeon, Yoon-Kyoung Cho
Summary: Immature dendritic cells (imDCs) change their migratory modes frequently, while mature dendritic cells (mDCs) do not show directional transitions. This study provides new insights into the complex migratory behavior of dendritic cells and highlights the importance of migration mode transition and maturation-dependent motility changes.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Jason M. Schenkel, Rebecca H. Herbst, David Canner, Amy Li, Michelle Hillman, Sean-Luc Shanahan, Grace Gibbons, Olivia C. Smith, Jonathan Y. Kim, Peter Westcott, William L. Hwang, William A. Freed-Pastor, George Eng, Michael S. Cuoco, Patricia Rogers, Jin K. Park, Megan L. Burger, Orit Rozenblatt-Rosen, Le Cong, Kristen E. Pauken, Aviv Regev, Tyler Jacks
Summary: In tumors, a subset of CD8(+) T cells expressing the transcription factor TCF-1 drives the response to immune checkpoint blockade. As tumors progress, intratumoral TCF-1(+) CD8(+) T cells acquire dysfunctional features and decrease in number, while their frequency in tumor draining LN remains stable. The decrease in conventional type I dendritic cells (cDC1) in dLN contributes to failed anti-tumor immunity by reducing the reservoir of TCF-1(+) CD8(+) T cells.
Article
Oncology
Francisco J. Cueto, Carlos Del Fresno, Paola Brandi, Alexis J. Combes, Elena Hernandez-Garcia, Alfonso R. Sanchez-Paulete, Michel Enamorado, Christian P. Bromley, Manuel J. Gomez, Ruth Conde-Garrosa, Santos Manes, Santiago Zelenay, Ignacio Melero, Salvador Iborra, Matthew F. Krummel, David Sancho
Summary: This study reveals that DNGR-1 restricts the accumulation of tumor-infiltrating cDC1s induced by Flt3L, and suggests that blocking DNGR-1 may enhance antitumor immunity in the context of high Flt3L expression in tumor therapy settings.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Immunology
Fernando Bandeira Sulczewski, Larissa Alves Martino, Davi Salles, Marcio Massao Yamamoto, Daniela Santoro Rosa, Silvia Beatriz Boscardin
Summary: In this study, the researchers investigated the role of the STAT3 signaling pathway in the ability of different types of dendritic cells to prime CD4(+) T cell responses. They found that STAT3 signaling pathway regulates the function of cDC1 to promote Th1 and Th1-like Tfh cell responses, but does not control the ability of cDC2 to promote Tfh cell responses.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Pavla Taborska, Dmitry Stakheev, Jirina Bartunkova, Daniel Smrz
Summary: The use of differentially activated human mast cell line LAD2 as a cellular adjuvant can modulate the maturation of ex vivo-produced monocyte-derived iDCs. This method is effective in modulating polyinosinic:polycytidylic acid (poly I:C)-elicited DC maturation in serum-containing media.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Zining Wang, Feifei Xu, Jie Hu, Hongxia Zhang, Lei Cui, Wenhua Lu, Wenzhuo He, Xiaojuan Wang, Mengyun Li, Huanling Zhang, Wenjing Xiong, Chunyuan Xie, Yongxiang Liu, Penghui Zhou, Jinyun Liu, Peng Huang, Xiaofeng Frank Qin, Xiaojun Xia
Summary: Clotrimazole was identified as a drug that could enhance DC-mediated antigen presentation and T cell response, by acting on hexokinase 2 to regulate metabolic production and enhancing the lysosome pathway and Chop expression in DCs. In vivo administration of clotrimazole induced immune infiltration and inhibited tumor growth, synergizing with anti-PD1 antibody therapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Xiaowu Bai, Chi Chun Wong, Yasi Pan, Huarong Chen, Weixin Liu, Jianning Zhai, Wei Kang, Yu Shi, Masami Yamamoto, Tetsuya Tsukamoto, Sachiyo Nomura, Philip Chiu, Jun Yu, Enders Kwok-wai Ng
Summary: YTHDF1 is overexpressed in gastric cancer and promotes cancer growth by inducing cell proliferation and suppressing dendritic cell-mediated anti-tumor immune response. YTHDF1 is a promising therapeutic target for gastric cancer treatment.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Immunology
Izumi Sasaki, Takashi Kato, Hiroaki Hemmi, Yuri Fukuda-Ohta, Naoko Wakaki-Nishiyama, Asumi Yamamoto, Tsuneyasu Kaisho
Summary: Dendritic cells (DC) are essential in connecting innate and adaptive immunity. Among the subsets, cDC1 plays a critical role in maintaining intestinal immune homeostasis.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Biotechnology & Applied Microbiology
Phillip Johnson, Nikita Rosendahl, Kristen J. Radford
Summary: Targeting cDC1 as a therapeutic option in cancer vaccines holds potential in improving tumor immunogenicity. Manipulation of cDC1 quantity and quality shows promise in enhancing the immune response in cancer patients. New technologies are advancing rapidly in understanding and generating cDC1 in vitro for clinical translation.
EXPERT OPINION ON BIOLOGICAL THERAPY
(2022)
Article
Oncology
Yoke Seng Lee, Liam J. O'Brien, Carina M. Walpole, Frances E. Pearson, Ingrid M. Leal-Rojas, Kelly-Anne Masterman, Victoria Atkinson, Andrew Barbour, Kristen J. Radford
Summary: The study found that the number of CD141(+) dendritic cells in the blood of melanoma patients was significantly reduced, and these cells exhibited impaired function after peripheral stimulation. In non-responding patients, the number and function of these cells continued to decline during treatment. Indirectly expanding and activating CD141(+) dendritic cells in vivo with Flt3L and a TLR3 agonist can enhance the efficacy of anti-PD-1 treatment.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Pharmacology & Pharmacy
Wenxiang Hong, Bo Yang, Qiaojun He, Jiajia Wang, Qinjie Weng
Summary: CCR7, along with its ligands CCL19 and CCL21, plays a crucial role in controlling migratory events in the immune system. Abnormal expression of CCR7 in dendritic cells can lead to inflammatory diseases due to disrupted dendritic cell trafficking. This review focuses on the structural-functional domains of CCR7 and its impact on dendritic cell migration to lymph nodes, as well as the regulatory network of CCR7. Furthermore, potential strategies targeting the CCR7 network to regulate dendritic cell migration and manage inflammatory diseases are discussed.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Immunology
Yuehan Gao, He Li, Zhaohuai Li, Lihui Xie, Xiuxing Liu, Zhaohao Huang, Binyao Chen, Xianchai Lin, Xianggui Wang, Yingfeng Zheng, Wenru Su
Summary: The study identified different subtypes within human moDCs and blood DCs, revealing their transcriptomic differences and differentiation trajectories, which will enable more accurate functional and developmental analyses of human cDC2s and moDCs.
JOURNAL OF IMMUNOLOGY
(2021)
Article
Oncology
Eva Ellebaek, Aimilia Schina, Henrik Schmidt, Charlotte Aaquist Haslund, Lars Bastholt, Inge Marie Svane, Marco Donia
Summary: This study found that initiation of immunotherapy in summer is associated with prolonged survival in patients with BRAF wild-type melanoma in Denmark.
PIGMENT CELL & MELANOMA RESEARCH
(2023)
Letter
Gastroenterology & Hepatology
Emilie Dahl, Osama Abed, Jorgen Agnholt, Jacob Bjerrum, Anders Dige, Jens Kjeldsen, Inge Svane, Marco Donia, Jakob Seidelin
Summary: This article is linked to Dahl et al papers. To view these articles, visit...
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Oncology
Neel Maria Helvind, Marie Brinch-Moller Weitemeyer, Annette Hougaard Chakera, Helle Westergren Hendel, Eva Ellebaek, Inge Marie Svane, Mette Wanscher Kjaerskov, Sophie Bojesen, Helle Skyum, Soren Kjaer Petersen, Lars Bastholt, Christoffer Johansen, Pernille Envold Bidstrup, Lisbet Rosenkrantz Holmich
Summary: This study aimed to determine the impact of surveillance with routine FDG PET-CT on hazard, cumulative incidence, and absolute risk of overall, locoregional, and distant recurrence detection in patients with stage IIB to IIID cutaneous melanoma. The study found that patients with stage IIB to IIID melanoma followed with routine FDG PET-CT had a 51% increased hazard of distant recurrence detection within the first two years of surveillance.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Review
Oncology
Tine J. Monberg, Troels H. Borch, Inge M. Svane, Marco Donia
Summary: Treatment with tumor-infiltrating lymphocytes (TIL) has been proven to be safe, feasible, and effective for patients with metastatic melanoma. However, its implementation on a larger scale is currently limited due to the lack of regulatory approvals. This review discusses the current knowledge of TIL therapy and addresses the practical, logistic, and economic challenges associated with its widespread implementation.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Arianna Draghi, Mario Presti, Agnete W. P. Jensen, Christopher A. Chamberlain, Benedetta Albieri, Anne-Christine K. Rasmussen, Mads H. Andersen, Michael D. Crowther, Inge Marie Svane, Marco Donia
Summary: Our study demonstrates that exploiting tumor-specific cytotoxic CD4(+) TILs could help overcome resistance to ICB mediated by IFN gamma-signaling loss in MHCIIconst(+) melanomas.
CLINICAL CANCER RESEARCH
(2023)
Article
Immunology
Sofie Kirial Mork, Per Kongsted, Marie Christine Wulff Westergaard, Benedetta Albieri, Joachim Stoltenborg Granhoj, Marco Donia, Evelina Martinenaite, Morten Orebo Holmstroem, Kasper Madsen, Anders H. Kverneland, Julie Westerlin Kjeldsen, Rikke Boedker Holmstroem, Cathrine Lund Lorentzen, Nis Norgaard, Lars Vibe Andreasen, Grith Kroyer Wood, Dennis Christensen, Michael Schantz Klausen, Sine Reker Hadrup, Per Thor Straten, Mads Hald Andersen, Inge Marie Svane
Summary: This study evaluated the tolerability and safety of a vaccine using Bcl-XL-peptide and CAF((R))09b as an adjuvant in patients with hormone-sensitive prostate cancer. The optimal route of administration and vaccine immunogenicity were also assessed. The vaccine was found to be feasible and safe, and it was able to induce immune responses. IP administration led to earlier and stronger vaccine-specific immune responses compared to IM administration.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Thomas Morgan Hulen, Christina Friese, Nikolaj Pagh Kristensen, Joachim Stoltenborg Granhoj, Troels Holz Borch, Marlies J. W. Peeters, Marco Donia, Mads Hald Andersen, Sine Reker Hadrup, Inge Marie Svane, Ozcan Met
Summary: Checkpoint inhibition (CPI) therapy and adoptive cell therapy with autologous tumor-infiltrating lymphocytes (TIL-based ACT) have shown to be highly effective immunotherapies for metastatic melanoma treatment. In this study, we investigated the changes in TIL qualities when the ex vivo microenvironment of intact tumor fragments were modulated with checkpoint inhibitors targeting PD-1 and CTLA-4. We found that unmodified TILs from CPI-resistant individuals could be produced, were terminally differentiated, and capable of responding to tumor. Furthermore, we confirmed the specificity of TILs to highly responding tumor antigens and identified the contribution of specific CD39(+)CD69(+) terminally differentiated populations.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Rasmus Erik Johansson Mortensen, Morten Orebo Holmstrom, Thomas Landkildehus Lisle, Jane P. Hasselby, Gro L. Willemoe, Ozcan Met, Inge Marie Svane, Julia Johansen, Dorte L. Nielsen, Inna M. Chen, Mads Hald Andersen
Summary: This study investigated the significance of TGF-beta-specific T-cell immunity in patients with pancreatic cancer treated with ICI combined with radiotherapy. The results showed that patients with a strong TGF-beta-specific immune response had longer progression-free and overall survival compared to those with a weak or no response. It was also found that TGF-beta-specific T cells could recognize and enhance immune responses. Thus, combining TGF-beta vaccination with ICI/radiotherapy may benefit patients with pancreatic cancer.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Cathrine Lund Lorentzen, Julie Westerlin Kjeldsen, Eva Ehrnrooth, Mads Hald Andersen, Inge Marie Svane
Summary: Summary: This study presented the long-term follow-up results of the IDO/PD-L1 vaccine and nivolumab combination therapy in cohort A, showing promising efficacy with high overall response rates and durable responses. However, cohort B did not show significant clinical effects.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Lasse Kjaer, Vibe Skov, Morten Kranker Larsen, Tobias Idor Boklund, Morten Andersen, Maria Kefala, Trine A. Knudsen, Christina Schjellerup Eickhardt-Dalboge, Thomas Stiehl, Johanne Gudmand-Hoyer, Jordan Snyder, Morten Holmstrom, Mads H. Andersen, Johnny T. Ottesen, Christina Ellervik, Hans C. Hasselbalch
Summary: The initial diagnosis of overt myeloproliferative neoplasms (MPNs) occurs when symptoms or complications lead to a patient seeking medical attention. In some MPN subgroups like essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are the drivers of the disease. This study follows a healthy individual with a CALR mutation from initial identification as CALR clonal hematopoiesis of indeterminate potential (CHIP) to the diagnosis of pre-MF, providing insights into pre-diagnostic dynamics that may aid in early diagnosis and intervention in MPN patients.
FRONTIERS IN ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Garry Dolton, Cristina Rius, Aaron Wall, Barbara Szomolay, Valentina Bianchi, Sarah A. E. Galloway, Md Samiul Hasan, Theo Morin, Marine E. Caillaud, Hannah L. Thomas, Sarah Theaker, Li Rong Tan, Anna Fuller, Katie Topley, Mateusz Legut, Meriem Attaf, Jade R. Hopkins, Enas Behiry, Joanna Zabkiewicz, Caroline Alvares, Angharad Lloyd, Amber Rogers, Peter Henley, Christopher Fegan, Oliver Ottmann, Stephen Man, Michael D. Crowther, Marco Donia, Inge Marie Svane, David K. Cole, Paul E. Brown, Pierre Rizkallah, Andrew K. Sewell
Summary: Tumor-infiltrating lymphocyte therapy can activate T cells of the immune system to target and eliminate solid cancers. Through the use of combinatorial peptide libraries and a proteomic database, the antigen specificities of persistent cancer-specific T cell receptors (TCRs) were identified after successful therapy for stage IV malignant melanoma. These TCRs were capable of targeting multiple tumor types through specific epitopes, and the atomic structures revealed the importance of a shared recognition motif. The ability of these multi-epitope targeting T cells to recognize cancer cells surpasses the recognition of individual epitopes, making them promising candidates for future immunotherapies.
Article
Oncology
Anne Vest Soerensen, Jakob Kjellberg, Rikke Ibsen, Lars Bastholt, Henrik Schmidt, Inge Marie Svane
Summary: This study aimed to investigate the health care costs and loss of productivity after implementing new agents for metastatic melanoma. The results showed that the implementation of targeted therapy and checkpoint inhibitors increased medicine costs more than three-fold for long-term survivors. However, total health care costs excluding medicine costs were lower for long-term survivors in 2012-2016 compared to 2007-2011. Importantly, productivity increased for long-term survivors in 2012-2016.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Immunology
Morten Orebo Holmstrom, Morten Andersen, Sofie Traynor, Shamaila Munir Ahmad, Thomas Landkildehus Lisle, Jacob Handlos Grauslund, Vibe Skov, Lasse Kjaer, Johnny T. Ottesen, Morten Frier Gjerstorff, Hans Carl Hasselbalch, Mads Hald Andersen
Summary: CALRmut specific T cells do not increase in the bone marrow after therapeutic cancer vaccination against mutant CALR, possibly due to a high burden of CALRmut cells compared to the number of effector T cells in the peripheral blood.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Multidisciplinary Sciences
Asha M. Rudjord-Levann, Zilu Ye, Lise Hafkenscheid, Sabrina Horn, Renske Wiegertjes, Mathias A. I. Nielsen, Ming Song, Caroline B. K. Mathiesen, Jesse Stoop, Sean Stowell, Per Thor Straten, Hakon Leffler, Sergey Y. Vakhrushev, Sally Dabelsteen, Jesper V. Olsen, Hans H. Wandall
Summary: By analyzing the expression of galectin-1, we found that it is upregulated in the extracellular matrix of multiple tumors. Further proteomic and phosphoproteomic analysis revealed that galectin-1 induces a tumor-associated macrophage phenotype with increased expression of PD-L1 and IDO1. Galectin-1 also stimulates IDO1 production through JAK/STAT signaling. The cellular source of galectin-1 in the extracellular matrix was identified as epithelial and stromal cells. Targeting galectin-1 has potential in immunotherapeutic treatment of human cancers.
Article
Oncology
Moon Hee Lee, Jason Theodoropoulos, Jani Huuhtanen, Dipabarna Bhattacharya, Petrus Jarvinen, Sara Tornberg, Harry Nisen, Tuomas Mirtti, Ilona Uski, Anita Kumari, Karita Peltonen, Arianna Draghi, Marco Donia, Anna Kreutzman, Satu Mustjoki
Summary: In this study, we investigated the expanded tumor-infiltrating lymphocytes (TILs) in patients with renal cell carcinoma (RCC) and explored their characteristics and ability to recognize the tumor using experimental and computational tools.
CANCER RESEARCH COMMUNICATIONS
(2023)